Acute effect of the renally excreted low-calorie sweetener, acesulfame potassium (Ace-K), on urinary glucose excretion in people with pre-diabetes.
About the study
Low-calorie sweeteners (LCS) have been widely used in food and beverages in recent decades. However, a recent World Health Organisation (WHO) report highlighted that people who consume LCS regularly have an increased risk of developing type 2 diabetes. Acesulfame potassium (Ace-K) is a widely used low-calorie sweetener that is absorbed from the gut and excreted in the urine.
We want to find out whether Ace-K consumption reduces the amount of glucose excreted in the urine in healthy individuals and people with pre-diabetes and type 2 diabetes, which would promote higher blood glucose levels.
Eligible participants will be required to attend 3 sessions (before and after the intervention), 8am to 1pm approximately each, separated at least 7 days.
Eligibility requirements
To be eligible for this study, you should be:
- Have pre-diabetes [if you are unsure, we will do a glucose tolerance test at the screen]
- Aaged 18 – 70 years
- Body mass index (BMI) 20 -40 kg/m2
Participants must be able to attend the Clinical Research Facility at the Adelaide Health and Medical Sciences Building on North Terrace.
Recruitment timeline
Start of recruitment: March 2026
End of recruitment: December 2027
Benefits
After successfully completing the trial, an honorarium of up to $300 will paid via EFT transfer to participants for their time.
